Drug Profile
Herpes simplex virus vaccine - VAXXIT
Alternative Names: HSV-1 vaccine - VAXXIT; HSV-2 vaccine - VAXXITLatest Information Update: 13 Sep 2023
Price :
$50
*
At a glance
- Originator VAXXIT
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Herpes simplex virus infections
Most Recent Events
- 13 Sep 2023 Herpes simplex virus vaccine is still in preclinical phase for Herpes simplex virus infections in Italy (VAXXIT pipeline; September 2023)
- 10 May 2016 Preclinical trials in Herpes simplex virus infections in Italy (unspecified route) (VAXXIT website)